Efficacy and safety of emerging immunotherapies in psoriasis.

Psoriasis is a common chronic inflammatory disease of the skin. Current biologic therapies are highly effective in the treatment of psoriasis, transforming the lives of patients with this significantly disabling disease. Advances in the understanding of the immunological pathogenesis of psoriasis have led to the development of new biologic therapies, targeting specific inflammatory cytokines upregulated in psoriasis. These include the IL-17 antagonists, secukinumab, brodalumab and ixekizumab; the IL-23 antagonists, guselkumab and tildrakizumab; and the oral small molecule therapies, tofacitinib and apremilast. Here, we review evidence for the efficacy and safety of these novel psoriasis therapies, providing clinicians with an overview of the next era in immunotherapy for psoriasis.
AuthorsZenas Z N Yiu, Richard B Warren
JournalImmunotherapy (Immunotherapy) Vol. 7 Issue 2 Pg. 119-33 ( 2015) ISSN: 1750-7448 [Electronic] England
PMID25713988 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antibodies, Monoclonal
  • Interleukin-17
  • Interleukin-23
  • Antibodies, Monoclonal (immunology, therapeutic use)
  • Humans
  • Immunotherapy (methods)
  • Interleukin-17 (antagonists & inhibitors, immunology)
  • Interleukin-23 (antagonists & inhibitors, immunology)
  • Psoriasis (drug therapy, immunology, pathology)
  • Skin (immunology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: